Login to Your Account



Bid by Astrazeneca's Lynparza fueled by phase III in breast

By Randy Osborne
Staff Writer

Monday, June 5, 2017

CHICAGO – Detailed results from the phase III OLYMPIAD trial testing Astrazeneca plc's PARP inhibitor, Lynparza, in BRCA-related metastatic breast cancer rang the plenary session bell and won accolades from ASCO president Daniel Hayes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription